Houston, August 28, 2025 — Leads & Copy — Marker Therapeutics, Inc. (Nasdaq: MRKR) announced that its CEO, Dr. Juan Vera, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The fireside chat is scheduled for Wednesday, September 10, 2025, from 12:30 – 1:00 p.m. EDT at the Lotte New York Palace Hotel.
Dr. Vera and Marker’s management team will also conduct one-on-one meetings with registered investors to discuss the Company’s Multi-Antigen Recognizing (MAR) T cell platform and clinical developments, including the recent update on the Company’s Phase 1 APOLLO study.
Investors can register and access the webcast through Marker’s Investor Relations website under “Events and Presentations”.
Marker Therapeutics, Inc. specializes in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. Clinical trials have demonstrated that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and showed durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes.
Contact:
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com
Source: Marker Therapeutics, Inc.
